Stay updated on COMBI-AD Trial: Dabrafenib + Trametinib in Melanoma
Sign up to get notified when there's something new on the COMBI-AD Trial: Dabrafenib + Trametinib in Melanoma page.

Latest updates to the COMBI-AD Trial: Dabrafenib + Trametinib in Melanoma page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedA new revision entry 'Revision: v3.5.4' was added to the revision history, and the previous 'Revision: v3.5.3' entry was removed. This updates the history to reflect the latest site revision.SummaryDifference0.0%

- Check21 days agoNo Change Detected
- Check29 days agoNo Change Detected
- Check36 days agoChange DetectedThe study record history now includes a newer submitted version dated 2026-04-21 and associated “more information” and results-related sections, indicating the trial’s core metadata and reporting content were updated. It replaces an earlier revision (v3.5.2) reference with the latest revision (v3.5.3), consistent with an updated ClinicalTrials.gov record version.SummaryDifference0.5%

- Check43 days agoChange DetectedAdded revision v3.5.2 and deleted revision v3.5.0.SummaryDifference0.0%

- Check72 days agoChange DetectedIn the log, Revision: v3.5.0 was added and Revision: v3.4.3 was crossed out.SummaryDifference0.0%

- Check79 days agoChange DetectedRevision: v3.4.3 was added, replacing v3.4.2.SummaryDifference0.0%

- Check108 days agoChange DetectedRevision: v3.4.2 was added as the latest version in the study's history, replacing the earlier v3.4.1. The notice about government funding and operating status was removed from the page.SummaryDifference0.3%

Stay in the know with updates to COMBI-AD Trial: Dabrafenib + Trametinib in Melanoma
Enter your email address, and we'll notify you when there's something new on the COMBI-AD Trial: Dabrafenib + Trametinib in Melanoma page.